Xenon Pharmaceuticals Inc. (XENE) Discusses Positive Top Line Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures TranscriptSeeking Alpha • 03/09/26
Xenon Pharmaceuticals Rallies After Pivotal Data Shows Major Drop In Monthly SeizuresBenzinga • 03/09/26
The 'Unprecedented' Results That Could Nab Xenon A GW- Or Intra-Cellular-Like DealInvestors Business Daily • 03/09/26
Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)GlobeNewsWire • 03/09/26
Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026GlobeNewsWire • 03/08/26
Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 02/26/26
Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 DataThe Motley Fool • 02/19/26
Polarean Expands Xenon MRI Platform into Cardiopulmonary Drug Development with Multi-Center PH-ILD StudyGlobeNewsWire • 01/20/26
Xenon Pharmaceuticals Inc. (XENE) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/12/26
Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/12/26
Xenon Pharmaceuticals: Derisked Pipeline Ahead Of Critical 2026 Phase 3 ReadoutSeeking Alpha • 12/18/25
Xenon Pharmaceuticals Inc. (XENE) Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch Preparation TranscriptSeeking Alpha • 12/10/25
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025GlobeNewsWire • 12/05/25
Why Is Xenon Pharmaceuticals (XENE) Up 9.7% Since Last Earnings Report?Zacks Investment Research • 12/03/25
Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025GlobeNewsWire • 12/03/25